|
Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies |
||||
| Non-T carrier (CC) |
T carrier (CT, TT) |
|||
|
|
||||
| Cases/controls |
Relative risk (95% confidence interval) |
Cases/controls |
Relative risk (95% confidence interval) |
|
|
|
||||
| Anti-CCP antibody-positive |
||||
| Smoking-negative |
59/511 |
1.00 |
37/146 |
2.17 (1.41–3.35) |
| Smoking-positive |
142/192 |
6.29 (4.51–8.77) |
73/50 |
12.54 (8.11–19.40) |
| Anti-CCP antibody-negative |
||||
| Smoking-negative |
47/511 |
1.00 |
17/146 |
1.36 (0.80–2.33) |
| Smoking-positive |
60/192 |
3.71 (2.51–5.46) |
23/50 |
5.87 (3.46–9.95) |
|
The combination of carriage or not of the 1858T variant of the PTPN22 gene and ever or never smoking were compared for groups stratified for anti-CCP antibodies. | ||||
Kokkonen et al. Arthritis Research & Therapy 2007 9:R56 doi:10.1186/ar2214 |
||||